Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 8:13:865782.
doi: 10.3389/fimmu.2022.865782. eCollection 2022.

Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani  1 , Kamran Mansouri  2 , Mohammad Sajad Emami Aleagha  3 , Narges Moasefi  3 , Niloofar Yavari  4 , Seyed Kazem Shakouri  5 , Sara Notararigo  6 , Ali Shojaeian  7 , Flemming Pociot  8 , Reza Yarani  8   9
Affiliations
Review

Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani et al. Front Immunol. .

Abstract

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Keywords: exosomes; extracellular vesicle; immunomodulation; therapy; type 1 diabetes; β-cell.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Extracellular vesicles characteristics and biogenesis.
Figure 2
Figure 2
Extracellular vesicle application in type 1 diabetes; EVs modulate inflammation while recovering β-cells. EVs, extracellular vesicles; BM, Bone marrow; iPSCs, induced pluripotent stem cells; Th, T helper cell; Treg, regulatory T cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Warshauer JT, Bluestone JA, Anderson MS. New Frontiers in the Treatment of Type 1 Diabetes. Cell Metab (2020) 31(1):46–61. doi: 10.1016/j.cmet.2019.11.017 - DOI - PMC - PubMed
    1. Gale EA. The Rise of Childhood Type 1 Diabetes in the 20th Century. Diabetes (2002) 51(12):3353–61. doi: 10.2337/diabetes.51.12.3353 - DOI - PubMed
    1. Norris JM, Johnson RK, Stene LC. Type 1 Diabetes-Early Life Origins and Changing Epidemiology. Lancet Diabetes Endocrinol (2020) 8(3):226–38. doi: 10.1016/S2213-8587(19)30412-7 - DOI - PMC - PubMed
    1. Guo X, Wang W. Challenges and Recent Advances in the Subcutaneous Delivery of Insulin. Expert Opin Drug Deliv (2017) 14(6):727–34. doi: 10.1080/17425247.2016.1232247 - DOI - PubMed
    1. von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and Future Therapies for Type 1 Diabetes. Diabetologia (2021) 64(5):1037–48. doi: 10.1007/s00125-021-05398-3 - DOI - PMC - PubMed

Publication types